Time-Cap Labs Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA
Time-Cap Labs is recalling Metformin Hydrochloride Extended-Release Tablets because FDA analysis found NDMA impurity above acceptable levels.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. Per the rubric, FDA Class II recalls with potential for adverse health consequences (such as NDMA impurity) are categorized as Severe (Score 4), as they are not Class I but involve significant health risks.
Plain-English summary
Time-Cap Labs, Inc. is recalling Metformin Hydrochloride Extended-Release Tablets, USP 500 mg. The product is manufactured by Marksans Pharma Limited and distributed nationwide. The recall involves 11,279 bottles with lot code XP9004 and an expiration date of 12/2020.
The recall was initiated because FDA analysis detected the impurity N-Nitrosodimethylamine (NDMA) above the acceptable intake level. This is a Class II recall, indicating a situation where use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences.
Consumers should stop using the recalled product and contact their healthcare provider or pharmacist for guidance on alternative treatment options. The product is available in 100-tablet bottles.
The recalled product
- Product
- METFORMIN HYDROCHLORIDE EXTENDED RELEASE (METFORMIN HYDROCHLORIDE)
- Brand
- METFORMIN HYDROCHLORIDE EXTENDED RELEASE
- Manufacturer
- Marksans Pharma Limited
- Category
- Drug — Prescription Drug
- Affected units
- 11,279
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- XP9004
- exp 12/2020
UPCs (3)
- 0349483624014
- 0349483623109
- 0349483623017
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · METFORMIN HYDROCHLORIDE EXTENDED RELEASE
- SevereDirect Rx Recalls Metformin Hydrochloride Extended Release Due to NDMA Impurity
FDA (Drugs) · 2020-11-11
- SeverePD-Rx Recalls Metformin Hydrochloride Extended Release Due to NDMA Impurity
FDA (Drugs) · 2020-11-11
- SeverePD-Rx Recalls Metformin Hydrochloride Extended Release Tablets Due to NDMA
FDA (Drugs) · 2020-11-11
- SevereMetformin Hydrochloride Extended Release Tablets Recalled for NDMA Impurity
FDA (Drugs) · 2020-11-11
- SevereTime-Cap Labs Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2020-11-11
Same hazard · ndma impurity
See all →- SeverePreferred Pharmaceuticals Recalls Metformin HCl Extended Release Tablets
FDA (Drugs) · 2021-05-26
- SevereNostrum Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2021-02-10
- SevereNostrum Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2021-01-20
- SevereDenton Pharma Recalls Metformin Hydrochloride Tablets Due to NDMA Impurity
FDA (Drugs) · 2020-11-11
- SevereNostrum Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2020-11-11